Weng Dan 4

What Happened

• Weng Dan, a director of Gyre Therapeutics, received a derivative award on 2026-06-10 representing a right to purchase 40,000 shares of the company's common stock. The Form 4 reports the acquisition price as $0.00 for the award (derivative instrument), indicating a granted option/award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-10 (Form 4 filed 2026-06-30 — filing appears late versus the usual two-business-day Form 4 requirement).
• Reported amount: Option/award covering 40,000 shares; reported acquisition price $0.00 (derivative).
• Shares owned after transaction: Not specified in the excerpt provided.
• Footnote: The option vests in 12 equal monthly installments through June 10, 2027, subject to continued service (per filing).
• Filing timeliness: The filing date (June 30, 2026) is later than the June 10 transaction date and likely late under normal Form 4 timing rules.

Context

• This was a grant of a derivative award (an option/right to purchase shares) that vests over time; it does not represent an immediate cash purchase or sale of shares. Such awards are commonly part of director compensation and do not by themselves indicate that the insider is buying or selling shares in the open market.